应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.04.008

摘要/Abstract

摘要： 目的探讨应用聚乙二醇干扰素α-2a联合利巴韦林治疗的慢性丙型肝炎(CHC)患者血清可溶性血管黏附蛋白-1(sVAP-1)和血清淀粉样蛋白A(SAA)水平变化及其临床意义。方法 2018年2月～2021年2月我院收治的CHC患者62例和同期体检者48例,CHC患者均接受聚乙二醇干扰素α-2a联合利巴韦林治疗24周。采用ELISA法检测血清sVAP-1和SAA水平,采用实时荧光定量PCR法检测血清HCV RNA载量。采用早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)考核疗效。结果 CHC患者血清sVAP-1和SAA水平分别为(164.0±29.3)μg/L和(3.0±0.6)mg/L,显著高于健康人【分别为(73.7±15.8)μg/L和(0.8±0.2)mg/L,P<0.05】;17例血清高载量CHC患者血清sVAP-1和SAA水平分别为(225.9±33.7)μg/L和(4.3±0.7)mg/L,显著高于26例中等等HCV RNA载量患者【分别为(156.7±28.4)μg/L和(3.0±0.5)mg/L,P<0.05】或19例低HCV RNA载量患者【分别为(118.7±22.0)μg/L和(1.8±0.3)mg/L,P<0.05】;获得病毒学应答患者血清SAA水平显著高于未获得应答患者【EVR:(4.1±0.7)mg/L对(2.2±0.5)mg/L,ETVR:(3.2±0.9)mg/L对(1.6±0.4)mg/L和SVR:(3.7±0.8)mg/L对(1.5±0.4)mg/L,P<0.05】,而应答与未应答患者血清sVAP-1水平无显著性差异(P>0.05)。结论 CHC患者血清sVAP-1和SAA水平升高,其变化与病毒复制水平可能有关。监测血清SAA水平变化或有助于预测CHC患者的抗病毒疗效。

关键词: 慢性丙型肝炎, 聚乙二醇干扰素α-2a, 利巴韦林, 可溶性血管黏附蛋白-1, 血清淀粉样蛋白A, 治疗, 应答

Abstract: Objective The aim of this study was to explore the implication of serum soluble vascular adhesion protein-1 (sVAP-1) and serum amyloid A (SAA) levels in patients with chronic hepatitis C (CHC) receiving pegylated interferon α-2a (peg-IFN-α-2a) and ribavirin standardized treatment. Methods 62 patients with CHC and 48 healthy persons were enrolled in our hospital between February 2018 and February 2022, and all patients with CHC were treated with peg-IFN α-2a and ribavirin for 24 weeks. Serum sVAP-1 and SAA levels were detected by ELISA, and serum HCV RNA load was detected by real-time fluorescence quantitative PCR. The virologic response was evaluated by early virologic response (EVR), end treatment virologic response (ETVR) and sustained virologic response (SVR). Results Serum sVAP-1 and SAA levels in patients with CHC were (164.0±29.3)μg/L and (3.0±0.6)mg/L, significantly higher than [(73.7±15.8)μg/L and (0.8±0.2)mg/L, P<0.05] in healthy persons; serum sVAP-1 and SAA levels in 17 CHC patients with high serum viral loads were (225.9±33.7)μg/L and (4.3±0.7) mg/L, significantly higher than [(156.7±28.4)μg/L and (3.0±0.5)mg/L, respectively, P<0.05] in 26 CHC patients with medium viral loads or [(118.7±22.0)μg/L and (1.8±0.3)mg/L, respectively, P<0.05] in 19 CHC patients with low viral loads; serum SAA levels in patients who responded to antiviral therapy were significantly higher than non-responders [EVR:(4.1±0.7)mg/L vs. (2.2±0.5)mg/L; ETVR:(3.2±0.9)mg/L vs. (1.6±0.4)mg/L and SVR:(3.7±0.8)mg/L vs.(1.5±0.4)mg/L, P<0.05], while there were no significant differences as respect to serum sVAP-1 levels between responders and non-responders (P>0.05). Conclusion Serum sVAP-1 and SAA levels in patients with CHC increase, and their changes are related to virus replication. It might be helpful by monitoring serum SAA level changes in predicting the antiviral efficacy in patients with CHC.

Key words: Hepatitis C, Pegylated interferon α-2a, Ribavirin, Soluble vascular adhesion protein-1, Serum amyloid A, Therapy, Response

杨凯, 张凯, 汪勇. 应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 484-487.

Yang Kai, Zhang Kai, Wang Yong. Implication of serum sVAP-1 and SAA levels in patients with chronic hepatitis C receiving pegylated interferon α-2a and ribavirin standardized treatment[J]. Journal of Practical Hepatology, 2023, 26(4): 484-487.

参考文献

[1] 揭育胜, 袁静, 张晓红,等. 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究. 中华肝脏病杂志, 2019, 27(2):123-127.
[2] Zheng Z, Sze CW, Keng CT, et al. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One, 2017, 12(9):e0184127.
[3] Naggie S. Hepatitis C virus, inflammation, and cellular aging: turning back time. Top Antivir Med, 2017, 25(1):3-6.
[4] Kurkijärvi R, Yegutkin GG, Gunson BK, et al. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology, 2000, 119(4):1096-1103.
[5] Lalor PF, Sun PJ, Weston CJ, et al. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion. Hepatology, 2007, 45(2):465-474.
[6] 赵昕峰, 吴亦栋, 高扬,等. 血清淀粉样蛋白A联合C反应蛋白检测在手足口病患儿中的诊断价值. 中华传染病杂志, 2016, 34(7):419-421.
[7] Lannergard A, Larsson A, Kragsbjerg P, et al. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest, 2003, 63(4):267-272.
[8] Lavie M, Voisset C, Vu-Dac N, et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology, 2006, 44(6):1626-1634.
[9] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙?透窝追乐沃改?2019年版). 实用肝脏病杂志, 2020, 23(1):33-52.
[10] 何涛君, 杨来智, 吴润香,等. 102例慢性丙型肝炎患者血清免疫球蛋白和补体水平变化. 实用肝脏病杂志, 2015, 18(5):538-539.
[11] 徐欢, 王广丽, 董丹丹,等. 聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究. 实用肝脏病杂志, 2022, 25(4):500-503.
[12] Kuo CH, Wei JN, Yang CY, et al. Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively. Int J Obes (Lond), 2019, 43(3):512-522.
[13] Noonan T, Lukas S, Peet GW, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol, 2013, 2(2):172-185.
[14] Ma Q, Manaenko A, Khatibi NH, et al. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab, 2011, 31(3):881-893.
[15] 顾敏晔, 顾国浩, 石亚玲,等. 血清淀粉样蛋白A在新型冠状病毒肺炎诊疗中的应用价值. 中华检验医学杂志, 2020, 43(9):935-938.
[16] 赵海潇, 刘伟贤, 周丽. 血清淀粉样蛋白A在刀豆球蛋白A诱导肝损伤中的作用. 中华实验外科杂志, 2017, 34(12):2132-2134.
[17] Kjellmo CA, Karlsson H, Nestvold TK, et al. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity. J Clin Lipidol, 2018, 12(1):193-202.
[18] Hari-Dass R, Shah C, Meyer DJ, et al. Serum amyloid A protein binds to outer membrane protein A of gram-negative bacteria. J Biol Chem, 2005, 280(19):18562-18567.
[19] 孟海妹, 魏蔚, 焦亚冲,等. 血清淀粉样蛋白A通过Toll样受体4途径诱导类风湿关节炎中性粒细胞胞外诱捕网形成. 中华风湿病学杂志, 2017, 21(6):404-408.
[20] 沈方方, 薛海燕, 曹兰芳. 血清淀粉样蛋白A在鉴别全身型幼年特发性关节炎患儿活动与感染中的意义. 中华全科医师杂志, 2019, 18(1):61-64.
[21] Lee JY, Hall JA, Kroehling L, et al. Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell, 2020, 180(1):79-91.
[22] 李明遥, 白云强, 刘毅. 系统性红斑狼疮患者血清基质金属蛋白酶-3水平及其在鉴别疾病活动与合并肺部感染的意义. 中华内科杂志, 2020, 59(1):58-61.
[23] Sorić Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol, 2021, 11:631299.
[24] Gschwantler M, Dulic M, Dulic-Lakovic E, et al. Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study. J Gastrointestin Liver Dis, 2014, 23(1):101-102.

应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨^*

Implication of serum sVAP-1 and SAA levels in patients with chronic hepatitis C receiving pegylated interferon α-2a and ribavirin standardized treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[2]	甄永利, 张亚飞, 张振华. 自身免疫性肝病患者甲状腺功能变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 508-511.
[3]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[4]	丁闪闪, 丁凯, 姜宁. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 536-539.
[5]	袁小兵, 陈慰慰, 刘小莉, 姜铭, 范向军. 根治性肝叶切除术治疗肝细胞癌患者外周血自然杀伤细胞活力变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(4): 544-547.
[6]	朱加猛, 范丽琴, 尹力, 吴柏华. 腹腔镜手术治疗巨大肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 564-567.
[7]	黄昱, 王卓, 任承纲, 张耀, 刘杨旸, 樊华, 何梅峰. PTGD后不同时间行LC治疗急性结石性胆囊炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 568-571.
[8]	曾林, 张勇, 罗九宝, 吉彩云, 丹娜. LC术后应用疏利通泄汤治疗慢性胆囊炎合并胆结石患者对胃肠功能的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 572-575.
[9]	刘泽军, 慕海峰, 陈升宝, 王春, 徐刚. LC联合LCBDE同步手术治疗胆囊结石合并胆总管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 576-579.
[10]	郑峰, 李彦荣, 罗卫军, 张晓超. 经胆囊后三角入路和经胆囊三角入路腹腔镜胆囊切除术治疗胆囊结石伴慢性胆囊炎患者疗效及对血清炎症因子的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 580-583.
[11]	周红飞, 陈钟, 顾宏, 沙德胜. 胆管空肠Roux-en-Y吻合联合皮下空肠盲袢埋藏术治疗肝胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 584-587.
[12]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[13]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[14]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[15]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.